0001415889-24-010228.txt : 20240403 0001415889-24-010228.hdr.sgml : 20240403 20240403213012 ACCESSION NUMBER: 0001415889-24-010228 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240401 FILED AS OF DATE: 20240403 DATE AS OF CHANGE: 20240403 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lyssikatos Joseph P CENTRAL INDEX KEY: 0001967150 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39247 FILM NUMBER: 24821392 MAIL ADDRESS: STREET 1: 6200 LOOKOUT ROAD CITY: BOULDER STATE: CO ZIP: 80301 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Enliven Therapeutics, Inc. CENTRAL INDEX KEY: 0001672619 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 811523849 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6200 LOOKOUT ROAD CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: 720-647-8519 MAIL ADDRESS: STREET 1: 6200 LOOKOUT ROAD CITY: BOULDER STATE: CO ZIP: 80301 FORMER COMPANY: FORMER CONFORMED NAME: IMARA Inc. DATE OF NAME CHANGE: 20160419 4 1 form4-04042024_010402.xml X0508 4 2024-04-01 0001672619 Enliven Therapeutics, Inc. ELVN 0001967150 Lyssikatos Joseph P C/O ENLIVEN THERAPEUTICS, INC. 6200 LOOKOUT ROAD BOULDER CO 80301 true true false false CHIEF SCIENTIFIC OFFICER 1 Common Stock 2024-04-01 4 M 0 12000 1.12 A 12000 D Common Stock 2024-04-01 4 S 0 2352 17.7242 D 9648 D Common Stock 2024-04-01 4 S 0 9577 18.8038 D 71 D Common Stock 2024-04-01 4 S 0 71 19.3578 D 0 D Common Stock 1117035 I See footnote Stock Option (right to buy) 1.12 2024-04-01 4 M 0 12000 0 D 2030-06-16 Common Stock 12000 260550 D The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. This transaction was executed in multiple trades at prices ranging from $17.335 to $18.255. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $18.35 to $19.325. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $19.355 to $19.36. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. The option, originally for 344,550 shares, is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on May 3, 2020. /s/ Ben Hohl, by power of attorney 2024-04-03